Related Experiment Video
Updated: Jul 4, 2026
06:54
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Transforming growth factor-beta (TGF-beta) and brain tumours
Rodney B Luwor1, Andrew H Kaye, Hong-Jian Zhu
1Department of Surgery, University of Melbourne, Level 6, Clinical Sciences Building, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. rluwor@unimelb.edu.au
Summary
Transforming growth factor-beta (TGF-beta) initially suppresses tumors but later promotes their growth and spread in brain cancers. Understanding this switch is key to developing new TGF-beta targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Transforming growth factor-beta (TGF-beta) is implicated in various diseases, including cancer, fibrosis, and autoimmunity.
- TGF-beta exhibits dual roles in tumor development, acting as a suppressor in early stages and a promoter in later stages.
- The molecular mechanisms driving the switch in TGF-beta's function during tumor evolution remain incompletely understood.
Purpose of the Study:
- To review the molecular mechanisms underlying the dual role of TGF-beta in brain tumors.
- To discuss how TGF-beta transitions from a tumor-suppressive to a tumor-progressive factor in the brain.
- To explore therapeutic strategies targeting TGF-beta in brain cancer.
Main Methods:
- Literature review of studies on TGF-beta in brain tumor development.
- Analysis of molecular pathways mediating TGF-beta's effects.
- Summary of current and emerging therapeutic agents targeting TGF-beta.
Main Results:
- TGF-beta initially inhibits tumor cell proliferation but is later subverted by tumors to promote invasion and metastasis.
- Tumor cells develop resistance to TGF-beta's growth-inhibitory signals, leading to enhanced malignancy.
- TGF-beta also contributes to immune evasion within the tumor microenvironment.
Conclusions:
- TGF-beta plays a complex, context-dependent role in brain tumor progression.
- Elucidating the switch mechanisms is crucial for effective therapeutic interventions.
- Targeting TGF-beta and related pathways offers potential for novel brain cancer treatments.
Related Concept Videos
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:00Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...